|
PSA
6.1 – 10.0 ng/ml
|
|
Gleason Score
|
Pathology Risk
|
Clinical
Stage
|
|
T1c
|
T2a
|
T2b
|
T2c
|
|
2-4
|
Confined
to Prostate
|
87
|
73-97
|
76
|
56-94
|
69
|
47-91
|
67
|
45-91
|
|
Spread to Prostate Capsule
|
13
|
3-27
|
24
|
6-44
|
31
|
9-53
|
33
|
9-55
|
|
Spread to Seminal Vesicles
|
0
|
0-0
|
0
|
0-0
|
0
|
0-0
|
0
|
0-0
|
|
Spread to Lymph Nodes
|
0
|
0-0
|
0
|
0-0
|
0
|
0-0
|
0
|
0-0
|
|
5-6
|
Confined
to Prostate
|
75
|
72-77
|
58
|
54-61
|
49
|
43-55
|
46
|
36-56
|
| |
Spread to Prostate Capsule
|
23
|
21-25
|
37
|
34-41
|
44
|
39-49
|
46
|
37-55
|
| |
Spread to Seminal Vesicles
|
2
|
2-3
|
4
|
3-5
|
5
|
3-8
|
5
|
2-9
|
| |
Spread to Lymph Nodes
|
0
|
0-1
|
1
|
0-2
|
2
|
1-3
|
3
|
1-6
|
|
3+4=7
|
Confined
to Prostate
|
54
|
49-59
|
35
|
30-40
|
26
|
22-31
|
24
|
17-32
|
|
Spread to Prostate Capsule
|
36
|
32-40
|
49
|
43-54
|
52
|
46-58
|
52
|
42-61
|
|
Spread to Seminal Vesicles
|
8
|
6-11
|
13
|
9-18
|
16
|
10-22
|
13
|
6-23
|
|
Spread to Lymph Nodes
|
2
|
1-3
|
3
|
2-6
|
6
|
4-10
|
10
|
5-18
|
|
4+3=7
|
Confined
to Prostate
|
43
|
35-51
|
25
|
19-32
|
19
|
14-25
|
16
|
10-24
|
| |
Spread to Prostate Capsule
|
47
|
40-54
|
58
|
51-66
|
60
|
52-68
|
58
|
46-69
|
| |
Spread to Seminal Vesicles
|
88
|
4-12
|
11
|
6-17
|
13
|
7-20
|
11
|
4-21
|
| |
Spread to Lymph Nodes
|
2
|
1-4
|
5
|
2-8
|
8
|
5-14
|
13
|
6-25
|
|
8-10
|
Confined
to Prostate
|
37
|
28-46
|
21
|
15-28
|
15
|
10-21
|
13
|
8-20
|
|
Spread to Prostate Capsule
|
48
|
39-57
|
57
|
48-65
|
57
|
48-67
|
56
|
43-69
|
|
Spread to Seminal Vesicles
|
13
|
8-19
|
17
|
11-26
|
19
|
11-29
|
16
|
6-29
|
|
Spread to Lymph Nodes
|
3
|
1-5
|
5
|
2-10
|
8
|
4-16
|
13
|
5-26
|
